Marex Group PLC (MRX) PT Raised to $42 at Jefferies

HSBC Downgrades Marex Group PLC (MRX) to Hold

HSBC analyst Carlos Gomez-Lopez downgraded Marex Group PLC (NASDAQ: MRX) from Buy to Hold with a price target of $36.00 (from $33.00).

The analyst comments: "We adjust our estimates and roll forward our valuation base, leading to an increase in our TP to USD36.00 (from... More

Marex Group PLC (MRX) PT Raised to $40 at Goldman Sachs

Goldman Sachs analyst Alexander Blostein raised the price target on Marex Group PLC (NASDAQ: MRX) to $40.00 (from $36.00) while maintaining a Buy rating.... More

KBW Reiterates Outperform on Marex Group PLC (MRX) Following 'Strong Revenue Beat'

Keefe, Bruyette & Woods analyst Kyle Voigt reiterated an Outperform rating and $36.00 price target on Marex Group PLC (NASDAQ: MRX).

The analyst commented: "Strong Revenue Beat in Quarter; MRX reported an adjusted $0.12 EPS beat to KBWe (and to consensus) on higher revenues (+$0.39) and higher non-operating income... More

Marex Group PLC (MRX) PT Raised to $45 at Citi

Citi analyst Chris Allen raised the price target on Marex Group PLC (NASDAQ: MRX) to $45.00 (from $39.00) while maintaining a Buy rating.

The analyst comments "In 4Q, MRX continued to see strong momentum across its businesses, with continued market share gains and solid growth in... More

Marex Group PLC (MRX) PT Raised to $43 at Barclays

Barclays analyst Benjamin Budish raised the price target on Marex Group PLC (NASDAQ: MRX) to $43.00 (from $39.00) while maintaining a Overweight rating.... More

Medicis Pharmaceutical Corp. (MRX) Tops Q4 EPS by 15c

Medicis Pharmaceutical Corp. (NASDAQ: MRX) reported Q4 EPS of $0.76, $0.15 better than the analyst estimate of $0.61. Revenue for the quarter came in at $415.6 million versus the consensus estimate of $370.72 million.

For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.